Compare Incyte Corporation (INCY) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Mercadolibre Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Mercadolibre Inc trades at $1,840.01 (market cap $98.35B). The key difference: Mercadolibre Inc is far larger — about 4× Incyte Corporation's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | MELI | |
|---|---|---|
Market Cap | $24.54B | $98.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $2.51K |
52-Week Low | $81.61 | $1.55K |
Enterprise Value | $20.04B | $106.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
MercadoLibre (MELI) trades at $1,828.29, up 0.22% with strong technical bullish signals from moving averages. The company demonstrates exceptional revenue growth, reaching $28.89 billion in 2025, though recent earnings misses and margin pressures from strategic investments have tempered investor enthusiasm. Analyst consensus remains strongly bullish with a $2,150 price target, representing 17.6% upside potential from current levels.
MELI's growth-first strategy is driving market share gains but sacrificing near-term profitability. The stock presents a compelling opportunity for long-term investors willing to tolerate margin volatility, though execution risks and competitive pressures in Latin American e-commerce warrant careful monitoring. Current valuation at 52.77 P/E reflects premium pricing for high-growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
